The tests
New hope for early detection
With a cancer diagnosis, early detection can be a matter of life and death. At Syantra, that urgency is what drives us, day in and day out. And that drive is paying off. We’ve created a platform to change the way cancer is detected and treated.
This isn’t theoretical.
The Syantra platform — Onco-ID™ — is currently being used in a global clinical study for breast cancer detection, and the data that's coming in (expected to be released in early 2025) is delivering results that can best be described as astonishing.
And we’re just getting started.
Onco-ID will soon be put to similar use in early detection of multiple forms of cancer: pancreatic, gastric, ovarian, blood, brain… We will leverage our patent-pending platform across every possible cancer and disease.
Onco-ID: Breast
A game-changing liquid biopsy
The first test created with Syantra’s platform, Onco-ID (Onco-Immune Detect, as it leverages signals sent by the body’s immune system), Onco-ID: Breast is a precision medicine tool that measures a panel of gene expression biomarkers from whole blood.
It then uses a software package, developed with machine learning, to interpret data and provide a positive or negative result. It’s a patent-pending molecular approach to breast cancer screening that can detect invasive disease at an early stage.
Take part in the International Identify Breast Cancer (IDBC) Clinical Study
Clinical studies are ongoing in Calgary, Canada, and Manchester, UK.
Through the ongoing IDBC international clinical study (NCT04495244), whole blood samples (2.5 ml) are being analyzed using Onco-ID Breast.
The participant group includes women aged 25 to 80 years with no breast surgery in the past year and no previous cancer diagnosis except non-melanoma skin cancer. Blood samples are collected around the time of screening mammography and before any biopsies or surgeries.
Announcements & stories
News about Syantra and its revolutionary approach to cancer screening.
